This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-preview: Archive
Unveiling Marathon Petroleum (MPC) Q2 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Marathon Petroleum (MPC) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
MPCNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
What Analyst Projections for Key Metrics Reveal About TransDigm (TDG) Q3 Earnings
by Zacks Equity Research
Evaluate the expected performance of TransDigm (TDG) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
TDGPositive Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Stay Ahead of the Game With Pfizer (PFE) Q2 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Pfizer (PFE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
PFENo Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Unveiling Imperial Oil (IMO) Q2 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top-and-bottom-line estimates for Imperial Oil (IMO), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
IMONegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Stay Ahead of the Game With Eaton (ETN) Q2 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Eaton (ETN) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
ETNNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Insights Into Suncor Energy (SU) Q2: Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Suncor Energy (SU), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
SUNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
What Analyst Projections for Key Metrics Reveal About Palantir Technologies (PLTR) Q2 Earnings
by Zacks Equity Research
Evaluate the expected performance of Palantir Technologies (PLTR) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
PLTRNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
What Analyst Projections for Key Metrics Reveal About Palantir Technologies (PLTR) Q2 Earnings
by Zacks Equity Research
Evaluate the expected performance of Palantir Technologies (PLTR) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
PLTRNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Gear Up for Amgen (AMGN) Q2 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
AMGNNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Unlocking Q2 Potential of Diamondback (FANG): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Diamondback (FANG), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
FANGNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
What Analyst Projections for Key Metrics Reveal About Fidelity National (FIS) Q2 Earnings
by Zacks Equity Research
Beyond analysts' top-and-bottom-line estimates for Fidelity National (FIS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
FISNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Countdown to Zoetis (ZTS) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
ZTSPositive Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Caterpillar (CAT) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Evaluate the expected performance of Caterpillar (CAT) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
CATNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Gear Up for Aflac (AFL) Q2 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Aflac (AFL) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
AFLPositive Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Countdown to MPLX LP (MPLX) Q2 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of MPLX LP (MPLX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
MPLXNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Ahead of The Williams Companies (WMB) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for The Williams Companies (WMB), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
WMBPositive Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Countdown to PSEG (PEG) Q2 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Beyond analysts' top-and-bottom-line estimates for PSEG (PEG), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
PEGNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Wall Street's Insights Into Key Metrics Ahead of Exxon (XOM) Q2 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of Exxon (XOM) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
XOMNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Exploring Analyst Estimates for BP (BP) Q2 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for BP (BP), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
BPNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SRPTNegative Net Change JAZZNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STOKPositive Net Change HRMYPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Talos Energy (TALO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Talos Energy (TALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TALOPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Tandem Diabetes Care, Inc. (TNDM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Tandem Diabetes Care (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TNDMNegative Net Change WATNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RPRXNegative Net Change ACIUNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Star Bulk Carriers (SBLK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Star Bulk Carriers (SBLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SBLKNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate